<DOC>
	<DOCNO>NCT00775619</DOCNO>
	<brief_summary>The objective study compare single-dose oral bioavailability Carvedilol 12.5 mg tablet Ranbaxy Laboratories Coreg 12.5 mg tablet Glaxosmithkline healthy , adult , human subject feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Carvedilol 12.5mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>The study conduct open label , balance , randomize , two-treatment , two-sequence , two-period , single-dose , crossover , bioavailability study carvedilol formulation compare carvedilol 12.5mg Ohm Laboratories , Inc. ( subsidiary Ranbaxy pharmaceutical Inc , USA ) CoregÂ® 12.5mg tablet ( contain carvedilol 12.5 mg ) GlaxoSmithKline , USA healthy , adult , male , human subject feed condition . Forty healthy , adult , human subject meet inclusion exclusion criterion describe protocol enrol study . Thirty-nine subject complete period study</detailed_description>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Be ' age range 1845 year . Be neither overweight underweight his/her height per Life Insurance Corporation lndia height/weight chart nonmedical case . Have voluntarily give write informed consent participate study . Be normal health determine medical history physical examination subject perform within :1.4 day prior commencement study . If female : Of childbearing potential , practice acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( [ UD ) , abstinence ; Is postmenopausal least 1 year ; Is surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) . History allergy 13adrenoceptor antagonist especially carvedilol . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination . Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . Female volunteer demonstrate positive pregnancy test . Female volunteer currently breastfeed . Presence value significantly different normal reference range ( define Appendix 5 ) and/or judge clinically significant haemoglobin , total white blood cell count , differential WBC count platelet count . Positive urinary screen test drug abuse ( opiate And cannabinoids ) Presence value significantly different normal reference range ( define Appendix 5 ) and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . Clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , epithelial cell ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . Clinically abnormal ECG Chest Xray . History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological haematological disease , diabetes , glaucoma , bronchial asthma , faint syncope . History psychiatric illness may impair ability provide write informed consent . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . History drug dependence excessive alcohol intake Habitual basis 2 unit alcoholic beverage per day ( 1 Unit equivalent half pint beer ! glass wine I measure spirit ) difficulty_ abstaininq duration study period . Use enzyme modifying drug within 30 day prior Day 1 study . Participation clinical trial within 12 week precede Day 1 study . A haemoglobin concentration le 7 % low limit reference range e.g . 13 gm % reference range 1448 gm screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>bioequivalence Carvedilol 12.5 mg tablet feed condition</keyword>
</DOC>